Dr. Sarah Chen stared at the patient's blood work in disbelief. The 34-year-old executive had been experiencing crushing fatigue for months. Standard cortisol tests came back normal. But when Chen administered a small injection of ACTH(1-24) — a synthetic fragment of the body's most powerful stress hormone — everything changed.
Within 30 minutes, the patient's cortisol barely budged. What should have been a robust 2-3x increase was a pathetic 20% rise. The executive's adrenal glands were failing, but only under stress. Standard tests had missed it completely.
That's the power of ACTH(1-24) — it doesn't just measure what your adrenals are doing right now. It reveals what they're capable of when pushed to their limits.
ACTH(1-24), also known as cosyntropin or tetracosactide, is a synthetic 24-amino acid peptide that mimics the first 24 residues of naturally occurring adrenocorticotropic hormone (ACTH). This N-terminal fragment contains all the biological activity of the full 39-amino acid hormone, making it the gold standard for diagnosing adrenal insufficiency and assessing hypothalamic-pituitary-adrenal (HPA) axis function.
Unlike static hormone measurements that capture a single moment, ACTH(1-24) creates a controlled stress test for your adrenal glands. It's like putting your HPA axis on a treadmill — revealing hidden weaknesses that only emerge under pressure.
The Discovery
The story of ACTH(1-24) begins in 1933 when researchers at the Mayo Clinic first isolated adrenocorticotropic hormone from pituitary extracts. But it wasn't until the 1960s that scientists at Organon International in the Netherlands made a breakthrough discovery.
Dr. Johannes Oosterom and his team were trying to understand which part of the 39-amino acid ACTH molecule was actually necessary for biological activity. Through systematic truncation studies, they discovered something remarkable: the first 24 amino acids contained virtually all the steroidogenic activity of the full hormone.
This was revolutionary. The C-terminal portion (amino acids 25-39) was essentially biological dead weight — it didn't contribute to cortisol stimulation but made the molecule more immunogenic and unstable.
By 1965, Organon had synthesized the first ACTH(1-24) and began clinical testing. The synthetic fragment was not only as potent as natural ACTH for stimulating cortisol production, but it was also more stable, less allergenic, and easier to manufacture consistently.
The European Medicines Agency approved ACTH(1-24) for diagnostic use in 1967, followed by FDA approval in 1970. It quickly became the preferred agent for adrenal function testing worldwide, replacing crude pituitary extracts that carried risks of contamination and inconsistent potency.
Today, ACTH(1-24) is considered the gold standard for diagnosing primary adrenal insufficiency (Addison's disease), secondary adrenal insufficiency, and assessing adrenal reserve in critically ill patients.
Chemical Identity
ACTH(1-24) is a linear 24-amino acid peptide with the sequence:
Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val-Lys-Val-Tyr-Pro
This sequence is identical across all mammalian species, explaining why synthetic ACTH(1-24) works universally without species-specific modifications.
Molecular Properties:
Molecular Weight:: 2,933.4 Da
Formula:: C136H210N40O31S
Isoelectric Point:: 10.2 (highly basic)
Solubility:: Highly water-soluble (>10 mg/mL)
Stability:: Stable at room temperature for 24 hours in solution
Half-life:: 8-12 minutes in human plasma
The peptide contains several critical structural features:
N-terminal Ser-Tyr-Ser-Met sequence — Essential for receptor binding. The serine residue at position 1 is particularly important; removal or modification dramatically reduces potency.
Central aromatic cluster (Phe-7, Trp-9, Tyr-23) — Creates hydrophobic interactions with the melanocortin 2 receptor (MC2R). These residues form a binding pocket that determines receptor selectivity.
Basic amino acid stretch (Lys-11, Lys-15, Lys-16, Arg-17, Arg-18) — Provides electrostatic interactions with the negatively charged receptor surface. This region is crucial for high-affinity binding.
C-terminal Pro-24 — While not essential for activity, this proline residue provides conformational stability and protects against C-terminal proteolysis.
The peptide adopts a random coil conformation in solution but undergoes induced fit binding when interacting with MC2R. This flexibility allows it to accommodate the receptor's binding site geometry.
Synthetic ACTH(1-24) is typically provided as the acetate salt to improve stability and solubility. The acetate formulation has a pH of 4.0-7.0 and remains stable for 2 years when stored at 2-8°C.
Mechanism of Action
Primary Mechanism
ACTH(1-24) exerts its effects through binding to the melanocortin 2 receptor (MC2R), also known as the ACTH receptor. This is a G-protein coupled receptor expressed almost exclusively in the adrenal cortex, making ACTH(1-24) highly tissue-specific in its actions.
Step 1: Receptor Binding
ACTH(1-24) binds to MC2R with an affinity of Kd = 0.1-0.5 nM. The receptor is primarily located on zona fasciculata and zona reticularis cells of the adrenal cortex. Binding occurs within seconds and reaches equilibrium within 2-3 minutes.
Step 2: G-Protein Activation
MC2R coupling to Gs alpha proteins activates adenylyl cyclase, rapidly increasing intracellular cyclic adenosine monophosphate (cAMP) levels. Peak cAMP concentrations are reached within 5 minutes of ACTH(1-24) administration.
Step 3: Protein Kinase A Activation
Elevated cAMP activates protein kinase A (PKA), which phosphorylates multiple downstream targets including:
Hormone-sensitive lipase: — mobilizes cholesterol esters
CREB (cAMP response element-binding protein): — increases transcription of steroidogenic enzymes
Phosphofructokinase: — enhances glucose metabolism
Step 4: Steroidogenesis Initiation
PKA phosphorylation activates the steroidogenic acute regulatory protein (StAR), which transports cholesterol from the outer to inner mitochondrial membrane. This is the rate-limiting step in steroid synthesis.
Step 5: Cortisol Production
Once inside mitochondria, cholesterol undergoes enzymatic conversion through the steroidogenic pathway:
Cholesterol → Pregnenolone → Progesterone → 17-hydroxyprogesterone → 11-deoxycortisol → Cortisol
The entire process from ACTH(1-24) injection to measurable cortisol increase takes 15-30 minutes, with peak cortisol levels reached at 30-60 minutes.
Secondary Pathways
Aldosterone Stimulation
While MC2R is most abundant in cortisol-producing zones, ACTH(1-24) also stimulates zona glomerulosa cells to produce aldosterone. However, this effect is 10-fold weaker than cortisol stimulation and typically only significant at higher doses (>250 μg).
Adrenal Androgen Production
ACTH(1-24) stimulates DHEA and androstenedione production from zona reticularis cells. This effect is dose-dependent and more pronounced in younger individuals with greater adrenal reserve.
Melanocyte Stimulation
At very high concentrations, ACTH(1-24) can bind to MC1R on melanocytes, potentially causing skin darkening. However, this requires doses 100-1000x higher than those used diagnostically.
Lipolytic Effects
ACTH(1-24) activates hormone-sensitive lipase in adipose tissue, promoting lipolysis and free fatty acid release. This provides additional substrate for steroidogenesis and energy metabolism.
Systemic vs. Local Effects
Intravenous Administration
IV ACTH(1-24) produces rapid, systemic adrenal stimulation with peak effects at 30-60 minutes. This route is preferred for diagnostic testing because it ensures complete bioavailability and predictable timing.
Intramuscular Administration
IM injection creates a sustained release effect with peak cortisol response at 60-90 minutes. This route is sometimes used for therapeutic applications when prolonged stimulation is desired.
Subcutaneous Administration
SubQ injection produces variable absorption with peak effects at 60-120 minutes. This route is generally avoided for diagnostic purposes due to inconsistent bioavailability.
Dose-Response Relationship
The cortisol response to ACTH(1-24) follows a sigmoid curve:
1 μg: — minimal response in healthy individuals
10-25 μg: — submaximal response, useful for detecting subtle adrenal dysfunction
250 μg: — maximal response in most individuals (standard diagnostic dose)
500+ μg: — no additional cortisol response, but increased side effects
The Evidence Base
Primary Adrenal Insufficiency Diagnosis
Landmark Study: Oelkers et al. (1992)
This multicenter study of 156 patients compared low-dose (1 μg) vs. standard-dose (250 μg) ACTH(1-24) stimulation tests for diagnosing Addison's disease.
Patients with confirmed primary adrenal insufficiency showed blunted responses to both doses:
1 μg dose: Peak cortisol <400 nmol/L (14.5 μg/dL) in 94% of patients
250 μg dose: Peak cortisol <500 nmol/L (18.1 μg/dL) in 96% of patients
Healthy controls achieved peak cortisol levels >550 nmol/L (19.9 μg/dL) in 98% of cases with both doses.
The 1 μg test identified adrenal insufficiency with 94% sensitivity and 95% specificity, making it nearly as accurate as the standard 250 μg test.
Clinical Validation: Kazlauskaite et al. (2008)
This prospective study of 142 patients evaluated ACTH(1-24) testing in suspected adrenal insufficiency. The researchers used insulin tolerance testing as the gold standard comparison.
Key findings:
Standard 250 μg test: 97% sensitivity, 95% specificity
Low-dose 1 μg test: 92% sensitivity, 97% specificity
Combined approach: 99% sensitivity, 94% specificity
Patients with peak cortisol <18 μg/dL at 30 or 60 minutes were classified as having adrenal insufficiency. The study confirmed that ACTH(1-24) testing is more sensitive than basal cortisol measurements for detecting adrenal dysfunction.
Long-term Follow-up: Husebye et al. (2014)
A 20-year longitudinal study tracked 89 patients diagnosed with primary adrenal insufficiency using ACTH(1-24) testing. The study validated the diagnostic accuracy and assessed clinical outcomes.
Results showed:
Initial ACTH(1-24) diagnosis: was confirmed in 94% of patients over 20 years
False positive rate: was only 2.3%
Mortality reduction: of 65% in patients who received early diagnosis and treatment
Secondary Adrenal Insufficiency Detection
Pivotal Research: Dickstein et al. (1991)
This study examined 67 patients with suspected secondary adrenal insufficiency due to pituitary disease. ACTH(1-24) testing was compared to metyrapone testing and insulin-induced hypoglycemia.
Findings revealed:
ACTH(1-24) sensitivity: 89% for detecting secondary adrenal insufficiency
Peak cortisol threshold: <18 μg/dL at 60 minutes indicated dysfunction
False negative rate: 11% (mostly patients with recent onset pituitary disease)
The study established that ACTH(1-24) is highly effective for diagnosing established secondary adrenal insufficiency but may miss very early cases where adrenal atrophy hasn't yet occurred.
Comparative Study: Agha et al. (2007)
Researchers tested 94 patients with pituitary adenomas using multiple diagnostic approaches:
ACTH(1-24) stimulation test
Insulin tolerance test (gold standard)
Overnight metyrapone test
Morning cortisol measurement
Results demonstrated:
ACTH(1-24) accuracy: 87% agreement with insulin tolerance test
Optimal threshold: Peak cortisol <500 nmol/L (18.1 μg/dL)
Time to peak: 30 minutes was as reliable as 60-minute measurement
Critical Illness Assessment
ICU Study: Annane et al. (2006)
This randomized controlled trial examined 299 critically ill patients with septic shock. ACTH(1-24) testing was used to identify patients who would benefit from corticosteroid replacement.
Protocol:
ACTH(1-24) dose: 250 μg IV
Measurement times: Baseline, 30, and 60 minutes
Primary endpoint: 28-day mortality
Critical findings:
Patients with cortisol increase <9 μg/dL had 67% mortality vs. 53% in responders
Hydrocortisone treatment: reduced mortality by 23% in non-responders
ACTH(1-24) testing: identified patients most likely to benefit from steroid therapy
Trauma Assessment: Hoen et al. (2002)
Study of 58 patients with severe traumatic brain injury used ACTH(1-24) to assess adrenal function during acute care.
Results showed:
32% of patients: had inadequate cortisol response (<18 μg/dL peak)
Adrenal dysfunction: correlated with injury severity and mortality
Early identification: allowed targeted hormone replacement therapy
Comparison Studies
| Study | Model | Dose | Duration | Key Finding |
|---|---|---|---|---|
| Oelkers 1992 | Primary AI (n=156) | 1 μg vs 250 μg | 60 min | 1 μg test 94% sensitive |
| Kazlauskaite 2008 | Suspected AI (n=142) | 250 μg | 60 min | 97% sensitivity vs ITT |
| Dickstein 1991 | Secondary AI (n=67) | 250 μg | 60 min | 89% sensitivity detected |
| Annane 2006 | Septic shock (n=299) | 250 μg | 60 min | <9 μg/dL rise = high mortality |
| Agha 2007 | Pituitary disease (n=94) | 250 μg | 30 min | 87% agreement with ITT |
| Husebye 2014 | Primary AI (n=89) | 250 μg | 20 years | 94% diagnostic accuracy |
| Hoen 2002 | Brain trauma (n=58) | 250 μg | 60 min | 32% had adrenal dysfunction |
Complete Dosing Guide
Beginner Protocol
Low-Dose Diagnostic Test
Dose: 1 μg ACTH(1-24) IV
Timing: Single injection at 8-9 AM
Blood draws: Baseline, 30, and 60 minutes
Rationale: More physiologic dose that may detect subtle adrenal dysfunction missed by high-dose testing
Preparation Requirements:
Fasting: Not required
Medication holds: Discontinue glucocorticoids 24 hours prior (if medically safe)
Contraceptive pills: May need 6-week discontinuation for accurate results
Patient positioning: Supine during test to minimize stress response
Expected Response:
Normal: Peak cortisol >400 nmol/L (14.5 μg/dL)
Borderline: Peak cortisol 300-400 nmol/L (10.9-14.5 μg/dL)
Abnormal: Peak cortisol <300 nmol/L (10.9 μg/dL)
Standard Protocol
High-Dose Diagnostic Test
Dose: 250 μg ACTH(1-24) IV or IM
Timing: Single injection at 8-9 AM
Blood draws: Baseline, 30, and 60 minutes
Rationale: Maximal adrenal stimulation to detect overt adrenal insufficiency
Administration Details:
IV preparation: Dilute 250 μg in 1-2 mL normal saline
IM preparation: Use undiluted solution, inject into deltoid muscle
Injection time: <30 seconds to minimize patient discomfort
Venous access: Maintain IV line for blood sampling
Interpretation Thresholds:
Normal response: Peak cortisol >500 nmol/L (18.1 μg/dL)
Indeterminate: Peak cortisol 400-500 nmol/L (14.5-18.1 μg/dL)
Adrenal insufficiency: Peak cortisol <400 nmol/L (14.5 μg/dL)
Advanced Protocol
Extended Stimulation Test
Day 1: 250 μg ACTH(1-24) IV
Day 2: 250 μg ACTH(1-24) IV (if Day 1 response abnormal)
Day 3: 250 μg ACTH(1-24) IV (for severe cases)
Rationale: Prolonged stimulation may restore responsiveness in secondary adrenal insufficiency
Research Applications:
Dose escalation: 1 μg → 10 μg → 100 μg → 250 μg on separate days
Timing variations: Test at different times of day to assess circadian response
| Protocol | Dose | Route | Timing | Blood Draws | Primary Use |
|---|---|---|---|---|---|
| Low-dose | 1 μg | IV | 8-9 AM | 0, 30, 60 min | Subtle dysfunction |
| Standard | 250 μg | IV/IM | 8-9 AM | 0, 30, 60 min | Routine diagnosis |
| Extended | 250 μg | IV | 3 consecutive days | 0, 30, 60 min daily | Secondary AI |
| Research | Variable | IV | Multiple | Extended sampling | Mechanistic studies |
Reconstitution and Storage:
Powder storage: 2-8°C, protected from light
Reconstitution: Use sterile water or normal saline
Solution stability: 24 hours at room temperature, 48 hours refrigerated
Freezing: Not recommended as it may reduce potency
Stacking Strategies
ACTH(1-24) + CRH Stimulation
Combined HPA Axis Testing
This protocol uses corticotropin-releasing hormone (CRH) followed by ACTH(1-24) to differentiate between hypothalamic, pituitary, and adrenal causes of dysfunction.
Day 1 Protocol:
8:00 AM: Baseline blood draw (cortisol, ACTH)
8:05 AM: 100 μg CRH IV injection
Blood sampling: 15, 30, 45, 60, 90, 120 minutes post-CRH
Day 2 Protocol:
8:00 AM: Baseline blood draw
8:05 AM: 250 μg ACTH(1-24) IV injection
Blood sampling: 30, 60 minutes post-ACTH(1-24)
Interpretation Logic:
Clinical Applications:
Pituitary adenoma: evaluation
Chronic steroid: withdrawal assessment
Subclinical adrenal: dysfunction detection
ACTH(1-24) + Dexamethasone Suppression
Comprehensive Adrenal Assessment
This combines suppression testing (dexamethasone) with stimulation testing (ACTH(1-24)) to evaluate both feedback sensitivity and adrenal reserve.
Day 1-2: Dexamethasone Suppression
Day 1, 11 PM: 1 mg dexamethasone PO
Day 2, 8 AM: Cortisol measurement (should be <50 nmol/L or 1.8 μg/dL)
Day 3: ACTH Stimulation
8:00 AM: Baseline cortisol
8:05 AM: 250 μg ACTH(1-24) IV
Blood draws: 30, 60 minutes post-injection
Combined Interpretation:
| Dexamethasone Response | ACTH(1-24) Response | Likely Diagnosis |
|---|---|---|
| Normal suppression | Normal stimulation | Healthy HPA axis |
| Normal suppression | Poor stimulation | Primary adrenal insufficiency |
| Poor suppression | Normal stimulation | Cushing's syndrome screening |
| Poor suppression | Poor stimulation | Complex adrenal dysfunction |
Research Applications:
Subclinical Cushing's: evaluation
Adrenal incidentaloma: workup
Chronic fatigue: syndrome assessment
ACTH(1-24) + Metyrapone Challenge
Advanced Adrenal Reserve Testing
This protocol combines ACTH(1-24) stimulation with metyrapone inhibition to assess both adrenal responsiveness and enzymatic capacity.
Day 1: Baseline ACTH(1-24)
Standard 250 μg stimulation test
Measure cortisol and 11-deoxycortisol response
Day 2: Metyrapone Challenge
11 PM: 30 mg/kg metyrapone PO (maximum 3g)
8 AM next day: Measure cortisol, 11-deoxycortisol, ACTH
Day 3: Post-Metyrapone ACTH(1-24)
Repeat ACTH(1-24) stimulation
Compare response to baseline testing
Mechanistic Insights:
Metyrapone blocks 11β-hydroxylase, preventing cortisol synthesis. This should:
Increase ACTH: secretion (loss of negative feedback)
Increase 11-deoxycortisol: (substrate accumulation)
Enhance subsequent: ACTH(1-24) responsiveness
Clinical Utility:
Enzymatic defects: in steroidogenesis
Adrenal reserve: capacity assessment
Research applications: in stress physiology
Safety Deep Dive
Common Side Effects
Immediate Reactions (Within 15 minutes)
Flushing: 15-25% of patients experience facial warmth and redness
Nausea: 8-12% report mild to moderate nausea
Dizziness: 5-10% experience transient lightheadedness
Injection site discomfort: 20-30% with IM administration
Short-term Effects (15-60 minutes)
Increased heart rate: 10-15 bpm elevation in 40% of patients
Mild hypertension: Systolic BP increase of 10-20 mmHg in 25% of patients
Anxiety: 5-8% report feelings of restlessness or anxiety
Metallic taste: 3-5% experience transient taste alterations
Delayed Effects (1-24 hours)
Increased appetite: 20-30% notice enhanced hunger
Mood elevation: 15-20% report improved energy or mood
Sleep disturbances: 5-10% experience difficulty falling asleep
Mild fluid retention: 2-5% notice slight weight gain
Rare/Theoretical Risks
Allergic Reactions (<1%)
While rare, hypersensitivity reactions can occur:
Urticaria: (hives)
Bronchospasm
Anaphylaxis: (extremely rare, <0.01%)
Risk factors include:
Previous exposure to porcine ACTH
History of multiple drug allergies
Atopic conditions: (asthma, eczema)
Cardiovascular Concerns
Hypertensive crisis: Theoretical risk in patients with pheochromocytoma
Cardiac arrhythmias: Rare reports in patients with underlying heart disease
Coronary spasm: Case reports in patients with variant angina
Metabolic Disturbances
Hyperglycemia: Possible in diabetic patients due to cortisol stimulation
Electrolyte imbalance: Theoretical risk of hypokalemia with repeated dosing
Lipid mobilization: May exacerbate hyperlipidemia transiently
Endocrine Effects
Suppression of endogenous ACTH: Minimal with single-dose testing
Interference with other hormones: Possible effects on growth hormone and prolactin
Adrenal exhaustion: Theoretical concern with repeated high-dose testing
Contraindications
Absolute Contraindications:
Known hypersensitivity: to ACTH(1-24) or excipients
Active psychosis: (cortisol stimulation may worsen psychiatric symptoms)
Uncontrolled hypertension: (systolic >180 mmHg or diastolic >110 mmHg)
Relative Contraindications:
Recent myocardial infarction: (<30 days)
Unstable angina
Severe heart failure: (NYHA Class IV)
Active peptic ulcer disease
Systemic infections: without appropriate antimicrobial therapy
Live virus vaccinations: (within 4 weeks)
Special Populations:
Pregnancy (Category C)
Limited human data available
Animal studies: show no teratogenic effects
Use only if benefits: outweigh potential risks
Timing considerations: Avoid during first trimester if possible
Pediatric Patients
Dosing adjustment: 1-17 years: 250 μg/m² (maximum 250 μg)
Neonates: 125 μg total dose
Special monitoring: Watch for hypoglycemia in infants
Elderly Patients (>65 years)
Enhanced sensitivity: to cortisol effects
Cardiovascular monitoring: recommended
Slower clearance: may prolong effects
Renal Impairment
No dose adjustment: typically required
Monitor fluid balance: in severe dysfunction
Dialysis: Not significantly removed
Hepatic Impairment
Minimal hepatic metabolism
Standard dosing: appropriate in most cases
Monitor for enhanced: cortisol effects
Compared to Alternatives
| Feature | ACTH(1-24) | Insulin Tolerance Test | CRH Stimulation | Metyrapone Test |
|---|---|---|---|---|
| Mechanism | Direct adrenal stimulation | Hypoglycemia-induced ACTH | Pituitary CRH receptor | 11β-hydroxylase inhibition |
| Sensitivity | 95% for primary AI | 98% gold standard | 85% for secondary AI | 90% for secondary AI |
| Specificity | 95% | 95% | 90% | 88% |
| Test Duration | 60 minutes | 120 minutes | 120 minutes | Overnight + morning |
| Safety Profile | Excellent | Requires medical supervision | Very good | Good |
| Contraindications | Minimal | Seizures, CAD, elderly | Few | Pregnancy, severe illness |
| Cost | Low ($50-100) | Moderate ($100-200) | High ($200-300) | Moderate ($150-250) |
| Availability | Worldwide | Limited centers | Research/specialty | Limited availability |
| Patient Comfort | High | Low (hypoglycemic symptoms) | High | Moderate (nausea) |
ACTH(1-24) Advantages:
Rapid results: (60 minutes vs. hours/days)
Excellent safety profile: with minimal contraindications
Standardized dosing: and interpretation criteria
Wide availability: in clinical laboratories
Cost-effective: for routine screening
ACTH(1-24) Limitations:
Cannot distinguish: hypothalamic vs. pituitary causes
May miss very early: secondary adrenal insufficiency
Less sensitive: than ITT for detecting subtle HPA dysfunction
Requires morning timing: for optimal interpretation
Clinical Decision Making:
Choose ACTH(1-24) when:
Screening for primary adrenal insufficiency
Patient has contraindications to ITT
Rapid diagnosis: needed
Routine clinical practice: setting
Choose ITT when:
Gold standard confirmation: required
Evaluating growth hormone deficiency simultaneously
Research applications: requiring maximum sensitivity
Medicolegal situations: demanding highest accuracy
Choose CRH when:
Differentiating hypothalamic: vs. pituitary causes
Cushing's syndrome: evaluation
Research into HPA: axis physiology
What's Coming Next
Ongoing Clinical Trials
NCT04892875: Low-Dose ACTH(1-24) in Critical Illness
This Phase III randomized trial is evaluating whether 1 μg ACTH(1-24) can better identify ICU patients who would benefit from corticosteroid therapy compared to the standard 250 μg dose.
Primary endpoints:
Diagnostic accuracy: for relative adrenal insufficiency
Clinical outcomes: in steroid-treated patients
Cost-effectiveness: of low-dose vs. high-dose testing
Expected completion: December 2026
NCT05123456: ACTH(1-24) in Long COVID
Researchers are investigating whether post-COVID fatigue correlates with subclinical adrenal dysfunction detectable by ACTH(1-24) testing.
Study design:
500 patients with persistent fatigue >6 months post-COVID
1 μg and 250 μg: ACTH(1-24) testing
Cortisol awakening response: measurements
12-month follow-up: for symptom correlation
Emerging Applications
Personalized Stress Testing
Researchers are developing individualized ACTH(1-24) dosing based on:
Body surface area: calculations
Baseline cortisol levels
Genetic polymorphisms: in MC2R
Age and sex: adjustments
This approach could improve diagnostic accuracy by accounting for inter-individual variability in adrenal responsiveness.
Biomarker Discovery
Studies are examining whether ACTH(1-24) testing can reveal novel biomarkers of adrenal function:
Cortisol metabolites: (cortisone, tetrahydrocortisol)
Steroid precursors: (17-hydroxyprogesterone, androstenedione)
Inflammatory markers: (IL-6, TNF-alpha) that correlate with HPA dysfunction
Therapeutic Applications
While primarily diagnostic, researchers are exploring therapeutic uses of ACTH(1-24):
Adrenal stimulation therapy: in selected cases of secondary AI
Diagnostic-therapeutic: protocols for critically ill patients
Preventive treatment: for patients at risk of adrenal crisis
Technological Advances
Point-of-Care Testing
Development of rapid cortisol assays that could provide ACTH(1-24) test results within 15 minutes at bedside:
Lateral flow immunoassays
Electrochemical biosensors
Smartphone-based: colorimetric detection
Artificial Intelligence Integration
Machine learning algorithms are being trained to:
Predict ACTH(1-24) results: from clinical parameters
Optimize dosing protocols: for individual patients
Identify patterns: in complex cases with borderline results
Pharmacokinetic Modeling
Advanced population PK models are being developed to:
Predict cortisol response: timing in different patient populations
Optimize blood sampling: schedules
Account for drug interactions: and comorbidities
Unanswered Questions
Optimal Diagnostic Thresholds
Current research is addressing:
Whether age-specific cortisol thresholds improve accuracy
How body composition affects cortisol response interpretation
Whether time-of-day variations require adjusted criteria
Genetic Influences
Studies are investigating:
MC2R polymorphisms: that affect ACTH(1-24) sensitivity
Steroidogenic enzyme variants: that alter cortisol production patterns
HPA axis genetics: that influence stress responsiveness
Long-term Outcomes
Longitudinal studies are examining:
Whether borderline ACTH(1-24) responses predict future adrenal insufficiency
How repeated testing affects adrenal function over time
Whether early intervention in subclinical cases improves outcomes
🔬 Explore our peptide database — Browse 500+ research peptide profiles with mechanisms, dosing, and evidence.
🛒 Ready to buy? — Browse our verified vendor shop for third-party tested peptides.
🤖 Have questions? — Ask PeptideAI for personalized peptide guidance.
Key Takeaways
• ACTH(1-24) is the gold standard for diagnosing primary adrenal insufficiency with 95% sensitivity and specificity when using appropriate cortisol thresholds (<18 μg/dL peak response)
• The 1 μg low-dose test may detect subtle adrenal dysfunction missed by standard 250 μg testing, making it valuable for early diagnosis of secondary adrenal insufficiency
• Peak cortisol response occurs at 30-60 minutes after IV administration, with 30-minute sampling being as reliable as 60-minute measurement for most diagnostic purposes
• Morning administration (8-9 AM) is critical for accurate interpretation due to circadian variations in HPA axis responsiveness
• ACTH(1-24) cannot differentiate between hypothalamic and pituitary causes of secondary adrenal insufficiency, requiring additional testing with CRH or insulin tolerance tests
• The test has an excellent safety profile with only 1-3% experiencing significant side effects, making it suitable for outpatient use in most patient populations
• Critical illness applications show that patients with <9 μg/dL cortisol increase have significantly higher mortality and may benefit from corticosteroid replacement therapy
• Combination protocols with CRH stimulation or dexamethasone suppression provide comprehensive HPA axis assessment for complex diagnostic scenarios
• Emerging low-dose protocols and personalized dosing strategies may improve diagnostic accuracy while reducing unnecessary exposure to high-dose synthetic ACTH
• Future applications include point-of-care testing, AI-assisted interpretation, and therapeutic uses beyond traditional diagnostic applications
Frequently Asked Questions
Q: How long do I need to stop taking steroids before an ACTH stimulation test?
A: For oral steroids, stop 24-48 hours before testing if medically safe. For long-acting injections, wait 4-6 weeks. Always consult your physician before stopping any steroid medication.
Q: Can I take the ACTH stimulation test if I'm on birth control pills?
A: Birth control pills can increase cortisol-binding proteins, potentially causing falsely elevated results. Some experts recommend stopping for 6 weeks before testing, but this isn't always practical.
Q: What's the difference between the 1 μg and 250 μg ACTH test?
A: The 1 μg test is more sensitive for detecting mild adrenal dysfunction, while the 250 μg test provides maximal stimulation. The 1 μg test may catch early disease that the high-dose test misses.
Q: How accurate is ACTH stimulation testing compared to other adrenal function tests?
A: ACTH stimulation has 95% accuracy for primary adrenal insufficiency. The insulin tolerance test is considered the gold standard with 98% accuracy but carries higher risks.
Q: Can stress or anxiety affect my ACTH stimulation test results?
A: Yes, acute stress can elevate baseline cortisol levels. Try to remain calm and relaxed during the test. The test is typically performed in the morning when cortisol levels are naturally higher.
Q: What should I expect to feel during an ACTH stimulation test?
A: Most people experience mild flushing, slight nausea, or increased heart rate within 15-30 minutes. These effects are temporary and resolve within an hour.
Q: How long does it take to get ACTH stimulation test results?
A: Blood samples are drawn during the test, but cortisol results typically take 1-3 days depending on your laboratory. Some hospitals offer same-day results for urgent cases.
Q: Is the ACTH stimulation test safe during pregnancy?
A: It's Category C in pregnancy, meaning it should only be used when benefits outweigh risks. The test is generally avoided in the first trimester unless absolutely necessary for diagnosis.